Shanghai Fosun Pharmaceutical (Group) Statistics

Total Valuation

Shanghai Fosun Pharmaceutical (Group) has a market cap or net worth of HKD 67.28 billion. The enterprise value is 100.66 billion.

Market Cap	67.28B
Enterprise Value	100.66B

Important Dates

The next estimated earnings date is Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	Jul 26, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+0.42%
Shares Change (QoQ)	+0.15%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.68B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.37, with an EV/FCF ratio of -439.13.

EV / Earnings	42.99
EV / Sales	2.25
EV / EBITDA	16.37
EV / EBIT	39.03
EV / FCF	-439.13

Financial Position

The company has a current ratio of 0.92, with a Debt / Equity ratio of 0.59.

Current Ratio	0.92
Quick Ratio	0.68
Debt / Equity	0.59
Debt / EBITDA	6.08
Debt / FCF	-168.03
Interest Coverage	1.66

Financial Efficiency

Return on equity (ROE) is 4.79% and return on invested capital (ROIC) is 1.64%.

Return on Equity (ROE)	4.79%
Return on Assets (ROA)	1.33%
Return on Capital (ROIC)	1.64%
Revenue Per Employee	1.14M
Profits Per Employee	57,997
Employee Count	40,370
Asset Turnover	0.37
Inventory Turnover	2.84

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.66% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-21.66%
50-Day Moving Average	14.42
200-Day Moving Average	13.47
Relative Strength Index (RSI)	39.91
Average Volume (20 Days)	4,282,045

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Shanghai Fosun Pharmaceutical (Group) had revenue of HKD 46.09 billion and earned 2.34 billion in profits. Earnings per share was 0.87.

Revenue	46.09B
Gross Profit	21.91B
Operating Income	2.66B
Pretax Income	3.37B
Net Income	2.34B
EBITDA	6.04B
EBIT	2.66B
Earnings Per Share (EPS)	0.87

Full Income Statement

Balance Sheet

The company has 17.31 billion in cash and 38.51 billion in debt, giving a net cash position of -21.20 billion.

Cash & Cash Equivalents	17.31B
Total Debt	38.51B
Net Cash	-21.20B
Net Cash Per Share	n/a
Equity (Book Value)	65.57B
Book Value Per Share	19.70
Working Capital	-3.31B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 4.36 billion and capital expenditures -4.59 billion, giving a free cash flow of -229.21 million.

Operating Cash Flow	4.36B
Capital Expenditures	-4.59B
Free Cash Flow	-229.21M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 47.55%, with operating and profit margins of 5.76% and 5.08%.

Gross Margin	47.55%
Operating Margin	5.76%
Pretax Margin	7.31%
Profit Margin	5.08%
EBITDA Margin	13.10%
EBIT Margin	5.76%
FCF Margin	-0.50%

Dividends & Yields

Shanghai Fosun Pharmaceutical (Group) does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	-34.78%
Years of Dividend Growth	n/a
Payout Ratio	97.52%
Buyback Yield	-0.42%
Shareholder Yield	-0.42%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Shanghai Fosun Pharmaceutical (Group) has an Altman Z-Score of 1.38. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.38
Piotroski F-Score	n/a